Analyzing the direct medical cost of Schizophrenia in Hospital Pulau Pinang, Malaysia
BACKGROUND: Schizophrenia (SCZ) is a major public health concern that places a significant economic burden on healthcare systems. This study assessed the direct medical costs of SCZ and examined cost drivers at Hospital Pulau Pinang (HPP), Malaysia. OBJECTIVE: To estimate and compare direct medical costs for SCZ patients across various healthcare services, including medications, diagnostics, hospitalizations, and outpatient care. METHODS: A retrospective, bottom-up costing analysis was conducted using medical records of all adult SCZ patients treated at HPP from 1 January 2019, to 27 April 2021. Data included demographic and clinical features, with costs categorized by service type. RESULTS: Among 120 patients (20 inpatients), 54.2% were female with a mean age of 39.5 ± 10.3 years. The mean annual inpatient cost per patient was MYR 8,483.4, with hospitalization alone contributing 62%. Outpatient costs averaged MYR 2,222 ± 2,571.9. CONCLUSIONS: SCZ treatment imposes a high financial burden, particularly due to hospitalization. These findings provide essential cost estimates to support healthcare planning and policy-making in Malaysia.
Authors
- Marwan Alrasheed (ORCID: https://orcid.org/0000-0001-8504-3779)
- Poh Yih Chew
- Abdulrahman A. Alsuhibani (ORCID: https://orcid.org/0000-0003-4852-1166)
- Ali Alhomaidan
- ONG Siew Chin
- Fuad Fadhel Alotaibi
Institutions
- Universiti Sains Malaysia (MY)
- Qassim University (SA)
- Hospital Pulau Pinang (MY)
- King Saud University (SA)
- Food and Drug Administration (TH)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2026-05-11
- DOI
- https://doi.org/10.1080/14737167.2026.2659625
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00